The primary outcomes assessed were levels of inflammatory markers such as IL-1β, IL-6, IL-8, IL-10, CRP, PCT, and TNF-α, providing a comprehensive overview of the effectiveness of the combined therapy on inflammatory responses in sepsis patients. The gene discussed is IL6; the disease is Sepsis.